Exploring the Role of Immunotherapy in the Management of Pulmonary Cancer

Roald Tolkien^*
*Correspondence: Roald Tolkien, Department of Pulmonary, University of Georgia, Athena, USA, Email:

Keywords

Cancer • Immune cells • Lung function

Introduction

Immunotherapy is a ground-breaking treatment strategy that harnesses the body's immune system to recognize and destroy cancer cells. Unlike traditional treatments that target the cancer cells directly, immunotherapy enhances the body's natural defense mechanisms, allowing the immune system to identify and eliminate cancer cells more effectively. This approach has shown remarkable success in various types of cancer, including pulmonary cancer. Checkpoint inhibitors are one of the most prominent types of immunotherapy used in pulmonary cancer treatment. These drugs block certain proteins on the surface of immune cells or cancer cells that inhibit immune responses. For instance, Programmed Death Receptor-1 (PD-1) inhibitors and Programmed Death-Ligand 1 (PD-L1) inhibitors prevent the interaction between cancer cells and immune cells, enabling the immune system to target and destroy cancer cells more efficiently.

Literature Review

Cytokines are signaling proteins that regulate immune responses. In pulmonary cancer, interleukin-2 (IL-2) and interferon-alpha are used to stimulate the immune system. IL-2 boosts the activity of immune cells, such as T cells and natural killer cells, which can recognize and attack cancer cells. Interferonalpha enhances the immune response and slows the growth of cancer cells. Cancer vaccines, including therapeutic and preventive vaccines, are being developed to train the immune system to recognize cancer cells as foreign invaders. Therapeutic vaccines are designed to stimulate an immune response against existing cancer cells, while preventive vaccines aim to prevent cancer recurrence or development in high-risk individuals. Chimeric antigen receptor (CAR) T-cell therapy involves engineering a patient's T cells to express specific receptors that can recognize cancer cells. These engineered T cells are then infused back into the patient, where they target and destroy cancer cells with high precision [1].

Immunotherapy has shown remarkable successes in the treatment of pulmonary cancer, particularly in cases where traditional therapies have failed. The use of checkpoint inhibitors like pembrolizumab and nivolumab has significantly improved overall survival rates and quality of life for advanced non-small cell lung cancer (NSCLC) patients. However, challenges. Not all patients respond equally to immunotherapy. Biomarker testing, such as PDL1 expression, is crucial in identifying patients who are more likely to benefit from immunotherapy. This personalized approach helps avoid unnecessary treatment and its associated costs and side effects [2].

Discussion

Some patients who initially respond to immunotherapy eventually develop resistance. Tumor heterogeneity, where cancer cells exhibit diverse characteristics, can lead to treatment resistance. Combining immunotherapy with other treatment modalities or developing strategies to overcome resistance is an ongoing challenge. While immunotherapy generally has fewer side effects than traditional treatments; it can still lead to immune-related adverse events, such as inflammation of the lungs (pneumonitis), skin (Dermatitis), or intestines (colitis). Early detection and management of these side effects are critical. Immunotherapy is often associated with high costs, which can limit access for some patients. Efforts to make these treatments more affordable and accessible are essential for realizing their full potential [3].

As the field of immunotherapy advances, ethical considerations come to the forefront. One of the major ethical concerns is the potential for unequal access to these ground-breaking treatments. Immunotherapy, although promising, can be financially burdensome and there is a risk that only patients with sufficient financial resources will be able to afford it. This raises questions about equity and social justice in healthcare. Efforts must be made to ensure that these treatments are accessible to all eligible patients, regardless of their socioeconomic status. Additionally, the ethical implications of combining immunotherapy with other treatments need careful consideration. While combination therapies might offer improved outcomes, they can also lead to increased side effects and potential harm to patients. Striking the right balance between maximizing treatment effectiveness and minimizing harm is a delicate ethical challenge that healthcare providers and researchers must navigate.

The most critical step in managing COPD is quitting smoking. Smoking cessation can help slow the decline in lung function and reduce exacerbations. Patient empowerment also plays a vital role in the success of immunotherapy. As patients become more informed about their treatment options, they can actively participate in shared decision-making with their healthcare providers. Understanding the potential benefits and risks of immunotherapy allows patients to make well-informed choices that align with their values and goals. Moreover, patient advocacy groups and support networks play a crucial role in raising awareness about immunotherapy, fostering patient education and advocating for equitable access to these treatments. The rapid advancements in immunotherapy for pulmonary cancer are largely driven by robust clinical trials and collaborative research initiatives. Clinical trials provide a platform to test new treatment approaches, evaluate their safety and efficacy and gather valuable data to guide clinical practice. Patients who participate in these trials contribute to the advancement of medical science and the development of improved treatment strategies. Rigorous oversight and adherence to ethical guidelines ensure patient safety during clinical trial participation. Research initiatives are also focused on understanding the mechanisms of immunotherapy resistance and exploring ways to overcome it. By uncovering the intricate interactions between cancer cells and the immune system, researchers aim to identify novel therapeutic targets and develop strategies to enhance treatment responses [4-6].

Conclusion

Immunotherapy has revolutionized the landscape of pulmonary cancer treatment. Its ability to harness the body's immune system to target and destroy cancer cells offers new hope for patients, especially those with advanced disease stages. As research continues to uncover the intricacies of immunotherapy and its interactions with pulmonary cancer, novel treatment strategies will emerge, leading to improved outcomes and better quality of life for patients. The collaboration between researchers, clinicians and pharmaceutical companies is key to realizing the full potential of immunotherapy in the fight against pulmonary cancer. Immunotherapy's focus on harnessing the body's natural defenses aligns well with the concept of patient-centric care. Rather than merely targeting cancer cells, immunotherapy aims to enhance the overall well-being of patients. By minimizing the debilitating side effects often associated with traditional treatments like chemotherapy, immunotherapy can significantly improve a patient's quality of life.

Acknowledgement

None.

Conflict of Interest

The authors declare that there is no conflict of interest associated with this manuscript.

References

1. Kwak, Jennifer J., Sree Harsha Tirumani, Annick D. Van den Abbeele and Phillip J. Koo, et al. "Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events." Radiographics 35 (2015): 424-437.

Google Scholar, Crossref, Indexed at

2. Disis, Mary L. "Mechanism of action of immunotherapy." Semin Oncol 41 (2014): S3-S13.

Google Scholar

3. Morse, Michael A., Paul J. Mosca, Timothy M. Clay and H. Kim Lyerly. "Dendritic cell maturation in active immunotherapy strategies." Expert Opin Biol Ther 2 (2002): 35-43.

Google Scholar, Crossref, Indexed at

4. Kokate, R. "A systematic overview of cancer immunotherapy: An emerging therapy." Pharm Pharmacol Int J 5 (2017): 31-35.

Google Scholar, Crossref, Indexed at

5. Hwang, William L., Luke RG Pike, Trevor J. Royce and Brandon A. Mahal, et al. "Safety of combining radiotherapy with immune-checkpoint inhibition." Nat Rev Clin Oncol 15 (2018): 477-494.

Google Scholar, Crossref, Indexed at

6. Braschi-Amirfarzan, Marta, Sree Harsha Tirumani, Frank Stephen Hodi and Mizuki Nishino. "Immune-checkpoint inhibitors in the era of precision medicine: What radiologists should know?" Korean J Radiol 18 (2017): 42-53.

Google Scholar, Crossref, Indexed at